Consequently, the impaired FA/BRCA pathway in KMT2D-deficient HNSCC under glycolytic inhibition renders these tumors hypersensitive to the combined treatment of glycolytic inhibitors and DNA-damaging agents or PARP inhibitors. The gene discussed is KMT2D; the disease is head and neck squamous cell carcinoma.